|
|
 Men Information - August 8, 2008
| The little blue pill that has transformed the lives of many men may be beneficial for some women on antidepressants who experience sexual dysfunction, a small trial has shown. Also known as sildenafil, the drug is often prescribed to help men's erectile dysfunction, but an eight-week study shows it helps women who experience sexual problems from antidepressant use | | Canadian health authorities have signaled bakers to follow fast-food chains example in cutting down the trans fat content of their products. The not-so-subtle hint came from MP Steven Fletcher, parliamentary secretary to Health Minister Tony Clement, who told the Toronto Star, "There is a possibility of regulation if industry doesn't meet the goals that have been outlined by the trans fat task force | | Health inspectors will on Saturday begin issuing citations and fines to New York City fast-food chain restaurants that fail to post calorie counts next to the prices on their menus. The new rule, allowing a two-month grace period, took effect in May. It marks the first time a U.S. city has launched an anti-obesity campaign. It requires restaurants that have 15 or more nationwide outlets to post calorie information beside their prices | | A new drug could potentially save the lives of thousands of prostate cancer sufferers, new studies have shown, while eliminating the need for damaging chemotherapy and radiotherapy. The drug, abiraterone, works by blocking the hormones which fuel the cancer and a human trial has shown that it can shrink tumors in up to 80 percent of cases. The technique could also be effective on other tumors, such as breast and bowel cancers, Britain's Daily Mail reported | | Most Canadian citizens are likely to survive the often fatal disease of cancer because of the country's accessible and reliable health care system, according to a Concord study. The study, which will appear in the August issue of The Lancet Oncology, revealed that Canada ranked second in patient survival for breast cancer, third for prostate cancer in men and for colorectal cancer in women, and sixth for colorectal cancer in men | |
|
|